ReviewArthritis research & therapy2012
Congenital heart block: evidence for a pathogenic role of maternal autoantibodies.
Review in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 108 citations in OpenAlex.
- Single Cell RNA Sequencing Reveals THBS1+CD14+ Monocyte Modulates Inflammatory Activation via NRLP3-Inflammasome in Congenital Heart Block.Journal of cellular and molecular medicine · 2026Article
- Multicenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti-Ro/La Antibody Detection in Primary Sjögren's Syndrome.Journal of immunology research · 2026Article
- Complete Heart Block in the Fetus: An Antenatal Complication of Sjögren's Syndrome.Life (Basel, Switzerland) · 2025Article
- Intrauterine Diagnosis and Treatment of High-Grade Atrioventricular Block: A Case Series and Literature Review.Clinical case reports · 2025Article
- Case Report: A multidisciplinary, protocol-driven pathway from recurrent pregnancy loss to live birth in an anti-Ro/SSA-positive primary Sjögren's syndrome pregnancy with literature review.Frontiers in immunology · 2025Review
- Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block.Acta obstetricia et gynecologica Scandinavica · 2024Article
- An unusual cause of cardiac arrest in a young infant.BMC cardiovascular disorders · 2024Article
- Congenital Complete Heart Block-To Stimulate (When?) or Not to Stimulate?Healthcare (Basel, Switzerland) · 2024Article
- Article
- Late-Onset Dilated Cardiomyopathy in Auto Immune-Mediated Complete Congenital Heart Block: A Case Report.Cureus · 2024Article
- Experience of treating congenital complete atrioventricular block with epicardial pacemaker in infants and young children: a retrospective study.BMC cardiovascular disorders · 2023Article
- Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.Annals of the rheumatic diseases · 2023Article
- Neutrophil Count as Atrioventricular Block (AVB) Predictor following Pediatric Heart Surgery.International journal of molecular sciences · 2022Article
- Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.Journal of perinatology : official journal of the California Perinatal Association · 2022Article
- Autoantibodies in Sjögren's syndrome and its classification criteria.Journal of translational autoimmunity · 2022Article
- Sjögren's syndrome and pregnancy: a Portuguese case-control study.Reumatologia · 2022Article
- Cardiovascular Disease in Primary Sjögren's Syndrome: Raising Clinicians' Awareness.Frontiers in immunology · 2022Review
- COVID-19 BBIBP-CorV vaccine and transient heart block - A phenomenon by chance or a possible correlation - A case report.Annals of medicine and surgery (2012) · 2021Article
- Prenatal Management Strategy for Immune-Associated Congenital Heart Block in Fetuses.Frontiers in cardiovascular medicine · 2021Review
- Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During pregnancy in autoimmune conditions, maternal autoantibodies are transported across the placenta and may affect the developing fetus. Congenital heart block (CHB) is known to associate with the presence of anti-Ro/SSA and anti-La/SSB antibodies in the mother and is characterized by a block in signal conduction at the atrioventricular (AV) node. The mortality rate of affected infants is 15% to 30%, and most live-born children require lifelong pacemaker implantation. Despite a well-recognized association with maternal anti-Ro/La antibodies, CHB develops in only 1% to 2% of anti-Ro-positive pregnancies, indicating that other factors are important for establishment of the block. The molecular mechanisms leading to complete AV block are still unclear, and the existing hypotheses fail to explain all aspects of CHB in one comprehensive model. In this review, we discuss the different specificities of maternal autoantibodies that have been implicated in CHB as well as the molecular mechanisms that have been suggested to operate, focusing on the evidence supporting a direct pathogenic role of maternal antibodies. Autoantibodies targeting the 52-kDa component of the Ro antigen remain the antibodies most closely associated with CHB. In vitro experiments and animal models of CHB also point to a major role for anti-Ro52 antibodies in CHB pathogenesis and suggest that these antibodies may directly affect calcium regulation in the fetal heart, leading to disturbances in signal conduction or electrogenesis or both. In addition, maternal antibody deposits are found in the heart of fetuses dying of CHB and are thought to contribute to an inflammatory reaction that eventually induces fibrosis and calcification of the AV node, leading to a complete block. Considering that CHB has a recurrence rate of 12% to 20% despite persisting maternal autoantibodies, it has long been clear that maternal autoantibodies are not sufficient for the establishment of a complete CHB, and efforts have been made to identify additional risk factors for this disorder. Therefore, recent studies looking at the influence of genetic and environmental factors will also be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.